Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Twist Bioscience Corporation reported revenue of $377M, up 20.3% year over year. Operating margin was -36.2% and net margin -20.6%, on a free-cash-flow margin of -20.1% with capital expenditure at 7.4% of revenue. Every figure is computed directly from TWST's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $377M | -36.2% | -20.6% |
| FY2024 | $313M | -70.6% | -66.7% |
| FY2023 | $245M | -88.6% | -83.5% |
| FY2022 | $204M | -115.3% | -107.0% |
| FY2021 | $132M | -115.4% | -114.9% |
How does TWST compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.